Objective: Acute pancreatitis is the most common complication of endoscopic retrograde
cholangiopancreatography (ERCP). Many medications have been used to prevent this complication. The purpose
of this study was to evaluate the efficacy of intravenous parecoxib sodium administered for the prevention of post-
Methods: During 9 months, all eligible patients who underwent ERCP were enrolled in this study.
Patients were randomly received an intravenous parecoxib sodium, 40 mg, immediately after ERCP or not. At the
end of each procedure, age, sex, indication of ERCP, findings and the details of the maneuvers performed were
recorded by endoscopists. Serum amylase levels and clinically pertinent evaluations were obtained in all patients
Results: A total of 60 patients entered the trial, of which half received parecoxib sodium. Eight patients
developed pancreatitis; four cases in the parecoxib sodium group and four cases in the control group. The procedures
characteristics and developing acute pancreatitis in each group did not show significant difference. Serum
amylase level at 4 hours post ERCP and next day seem to be lower but not significant in parecoxib sodium group
compared to those among control group.
Conclusions: Considering a relatively small sample size of the present study, intravenous administration
of parecoxib sodium immediately after ERCP could not reduce the incidence and severity of post-ERCP pancreatitis.